X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5) 5
economics, pharmaceutical (4) 4
aged (3) 3
anti-inflammatory agents, non-steroidal - adverse effects (3) 3
anti-inflammatory agents, non-steroidal - economics (3) 3
anti-inflammatory agents, non-steroidal - therapeutic use (3) 3
cost of illness (3) 3
cost-benefit analysis (3) 3
drug therapy, combination (3) 3
female (3) 3
health administration (3) 3
health care sciences & services (3) 3
health economics (3) 3
male (3) 3
medicine & public health (3) 3
middle aged (3) 3
nonsteroidal antiinflammatories, therapeutic use (3) 3
osteoarthritis, treatment (3) 3
pharmacoeconomics (3) 3
pharmacoeconomics and health outcomes (3) 3
pharmacology & pharmacy (3) 3
quality of life research (3) 3
rheumatoid arthritis, treatment (3) 3
rheumatoid-arthritis (3) 3
adult (2) 2
anti-ulcer agents - economics (2) 2
anti-ulcer agents - therapeutic use (2) 2
arthritis, rheumatoid - drug therapy (2) 2
arthritis, rheumatoid - economics (2) 2
care and treatment (2) 2
celecoxib, therapeutic use (2) 2
cost effectiveness (2) 2
decision trees (2) 2
diclofenac/misoprostol, therapeutic use (2) 2
digestive-system-ulcer (2) 2
double-blind (2) 2
duodenal ulcer - chemically induced (2) 2
duodenal ulcer - economics (2) 2
duodenal-ulcers (2) 2
gastroduodenal safety (2) 2
gastrointestinal-toxicity/disease management, drug therapy, side effect (2) 2
health-care-utilization (2) 2
misoprostol, therapeutic use (2) 2
nonsteroidal antiinflammatory drugs (2) 2
nsaid induced gastrointestinal damage, prevention (2) 2
osteoarthritis - drug therapy (2) 2
osteoarthritis - economics (2) 2
placebo-controlled trial (2) 2
proton pump inhibitors, therapeutic use (2) 2
randomized controlled trial (2) 2
resource-allocation (2) 2
administration, oral (1) 1
adolescent (1) 1
amoxicillin-potassium clavulanate combination - administration & dosage (1) 1
amoxicillin-potassium clavulanate combination - economics (1) 1
amoxicillin-potassium clavulanate combination - therapeutic use (1) 1
analysis (1) 1
anemia - chemically induced (1) 1
anemia - economics (1) 1
anti-infective agents - administration & dosage (1) 1
anti-infective agents - economics (1) 1
anti-infective agents - therapeutic use (1) 1
antiinflammatory drugs (1) 1
antineoplastic combined chemotherapy protocols - economics (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
arthritis - drug therapy (1) 1
arthritis, rheumatoid - epidemiology (1) 1
arthritis/disease management, drugtherapy (1) 1
aza compounds (1) 1
bacterial (1) 1
bacterial pneumonia (1) 1
british population (1) 1
canada (1) 1
carcinoma (1) 1
celecoxib (1) 1
chemotherapy (1) 1
chemotherapy, adjuvant - economics (1) 1
child (1) 1
clarithromycin (1) 1
clinical trials as topic (1) 1
clinical-trials (1) 1
colon cancer (1) 1
colonic neoplasms - drug therapy (1) 1
colonic neoplasms - economics (1) 1
colonic neoplasms - surgery (1) 1
community-acquired infections (1) 1
community-acquired infections - drug therapy (1) 1
community-acquired infections - economics (1) 1
cost (1) 1
cost analysis (1) 1
cost benefit analysis (1) 1
cost-benefit-analysis (1) 1
cost-effectiveness-analysis (1) 1
costs and cost analysis (1) 1
cyclo oxygenase 2 inhibitors, therapeutic use (1) 1
cyclooxygenase inhibitors - economics (1) 1
cyclooxygenase inhibitors - therapeutic use (1) 1
determinants (1) 1
direct service costs (1) 1
disablement (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Chest, ISSN 0012-3692, 08/2003, Volume 124, Issue 2, pp. 526 - 535
Journal Article
PharmacoEconomics, ISSN 1170-7690, 2001, Volume 19, Issue Supplement 1, pp. 59 - 75
Objective: The aim of this study was to predict the cost effectiveness of celecoxib, a cyclo-oxygenase 2 (COX-2) specific inhibitor, in the treatment of... 
Nonsteroidal antiinflammatories, therapeutic use | NSAID induced gastrointestinal damage, prevention | Misoprostol, therapeutic use | Proton pump inhibitors, therapeutic use | Cost effectiveness | Celecoxib, therapeutic use | Cyclo oxygenase 2 inhibitors, therapeutic use | Osteoarthritis, treatment | Rheumatoid arthritis, treatment | Histamine H2 receptor antagonists, therapeutic use | Pharmacoeconomics | Diclofenac/misoprostol, therapeutic use | Quality of Life Research | Health Economics | Health Administration | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | RHEUMATOID-ARTHRITIS | RANDOMIZED CONTROLLED TRIAL | DUODENAL-ULCERS | GASTRODUODENAL SAFETY | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | HIGH-RISK | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | PREVENTION | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | MISOPROSTOL | Anti-Ulcer Agents - economics | Humans | Cost of Illness | Duodenal Ulcer - chemically induced | Duodenal Ulcer - economics | Drug Therapy, Combination | Anti-Ulcer Agents - therapeutic use | Economics, Pharmaceutical | Pyrazoles | Anti-Inflammatory Agents, Non-Steroidal - economics | Anemia - chemically induced | Probability | Clinical Trials as Topic | Celecoxib | Switzerland | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cyclooxygenase Inhibitors - economics | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Cost-Benefit Analysis | Sulfonamides - economics | Arthritis - drug therapy | Anemia - economics | Decision Trees | Cyclooxygenase Inhibitors - therapeutic use
Journal Article
PharmacoEconomics, ISSN 1170-7690, 2001, Volume 19, Issue Supplement 1, pp. 49 - 58
Objective: To construct a decision analytical model to compare the costs and clinical consequences of treating patients with celecoxib or various nonsteroidal... 
Nonsteroidal antiinflammatories, therapeutic use | NSAID induced gastrointestinal damage, prevention | Histamine H2 receptor agonists, therapeutic use | Misoprostol, therapeutic use | Proton pump inhibitors, therapeutic use | Celecoxib, therapeutic use | Osteoarthritis, treatment | Rheumatoid arthritis, treatment | Pharmacoeconomics | Diclofenac/misoprostol, therapeutic use | Cost analysis | Resource use | Quality of Life Research | Health Economics | Health Administration | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | RHEUMATOID-ARTHRITIS | RANDOMIZED CONTROLLED TRIAL | DUODENAL-ULCERS | GASTRODUODENAL SAFETY | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | MUCOSAL INJURY | CLINICAL-TRIALS | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | INDUCED GASTROPATHY | Anti-Ulcer Agents - therapeutic use | Economics, Pharmaceutical | Anti-Ulcer Agents - economics | Anti-Inflammatory Agents, Non-Steroidal - economics | Humans | Cost of Illness | Duodenal Ulcer - chemically induced | Models, Economic | Osteoarthritis - drug therapy | Osteoarthritis - economics | Canada | Duodenal Ulcer - economics | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Arthritis, Rheumatoid - drug therapy | Duodenal Ulcer - drug therapy | Aged | Decision Trees | Drug Therapy, Combination | Arthritis, Rheumatoid - economics | Hospitalization - economics
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.